About Zealand Pharma
Zealand Pharma is a biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs. The products target diseases and symptoms of significant unmet clinical need and commercial potential.
Since 1999, Zealand’s scientists have built a pipeline that includes three compounds in clinical phase II development and two compounds in clinical phase I development. In addition, two compounds are in pre-clinical development.
As part of the Company’s operations, Zealand Pharma has formed clinical development partnerships with leading pharmaceutical companies Sanofi-Aventis and Wyeth.
- Focus : Manufacturer
- Industry : Biotechnology
Product portfolio of Zealand Pharma
News about Zealand Pharma
23-Jun-2022 | business & finance
Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design
Collaboration leverages Iktos’ capabilities in machine learning and AI and Zealand expertise in peptide drug discovery
08-Jan-2013 | people
Zealand Pharma appoints new Chief Operating Officer
Zealand Pharma (ZEAL) announces the appointment of Agneta Svedberg as the company’s new Chief Operating Officer. Effective from 1 February 2013, she will ...
17-Sep-2012 | research and development
Zealand Pharma advances ZP2929 into Phase I development for the treatment of Type 2 diabetes and/or obesity
First study participant dosed in a Phase I study with novel dual acting glucagon/GLP-1 peptide agonist in partnership with Boehringer Ingelheim
06-Mar-2012 | research and development
Zealand Pharma and Helsinn announce the advance of elsiglutide into Phase II for the prevention of chemotherapy-induced diarrhea in cancer patients
First patients dosed in Phase IIa study of novel GLP-2 peptide agonist
29-Jun-2011 | research and development
Zealand Pharma presented new preclinical data on ZP2929 in disease models for diabetes and obesity
ZP2929 caused a greater loss in body weight and fat mass as compared to treatment with liraglutide, a marketed GLP-1 agonist
17-Jun-2011 | research and development
Zealand Pharma and Boehringer Ingelheim enter into a licence and collaboration agreement to advance novel compounds to treat Type-2 diabetes and obesity
Boehringer Ingelheim obtains global rights to glucagon/GLP-1 dual agonists, including ZP2929, Zealand Pharma’s lead drug candidate in this class
01-Jun-2011 | research and development
Zealand Pharma: Additional positive Phase III results with Lyxumia (lixisenatide) for the treatment of Type 2 diabetes
Zealand Pharma A/S announced that its partner, Sanofi has released additional positive results from the global GetGoal Phase III development program with ...